Cytotoxic Properties of Sunitinib and Sorafenib on Human Corneal Epithelial Cells

References

• Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:264–302
   PubMedGoogle Scholar
• Pérez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M, Javaloy J, Alio JL. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010;150:519–528
   PubMed Web of Science ®Google Scholar
• Amano S, Rohan A, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18–22
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998;17:611–613
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000;19:526–533
   PubMed Web of Science ®Google Scholar
• Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea 1987;6:250–257
   PubMed Web of Science ®Google Scholar
• Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557–563
   PubMedGoogle Scholar
• Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, Laibson PR, et al. Corneal neovascularization after penetrating keratoplasty. Cornea 1995;14:604–609
   PubMed Web of Science ®Google Scholar
• Hill JC, Maske R. An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 1988;46:26–30
   PubMedGoogle Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147–1157
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331–335
   PubMed Web of Science ®Google Scholar
• Dell S, Peters S, Muther P, Kociok N, Joussen AM. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 2006;47:1928–1937
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of antivascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036–2053
   PubMed Web of Science ®Google Scholar
• Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008;27:349–352
   PubMedGoogle Scholar
• Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804–807
   PubMed Web of Science ®Google Scholar
• Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006;84:282–288
   PubMedGoogle Scholar
• Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323–328
   PubMed Web of Science ®Google Scholar
• Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158–160
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884–896
   PubMed Web of Science ®Google Scholar
• Pankaj Bhargava, Murray O. Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 2011;13:103–111
   PubMedGoogle Scholar
• de Paiva CS, Chen Z, Corrales RM, Pflugfelder SC, Li DQ. ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells. Stem Cells 2005;23:63–73
   PubMed Web of Science ®Google Scholar
• Reidy JJ, Hershberger DH, Campbell LM, Seigel GM. p63 and ABCG2 expression in the corneoscleral limbus: implications for stem cell purification. Invest Ophthalmol Vis Sci 2004;45:E–Abstract 3393
   Google Scholar
• Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977–982
   PubMed Web of Science ®Google Scholar
• Seo JW, Chung SH, Choi JS, Joo CK. Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. Cornea 2012;31:907–912
   PubMed Web of Science ®Google Scholar